Effects of Cilostazol and Diltiazem Hydrochloride on Ischemia-Reperfusion Injury in a Rat Hindlimb Model
Objective: Free radicals and neutrophils are potent sources of ischemia-reperfusion injury (I/R) and they can be limited by the use of exogenous application of some therapeutic agents. The objective of this study was to compare the effects of cilostazol and diltiazem hydrochloride in a rat hind limb model of I/R injury.
Methods: Skeletal muscles submitted to 2 hours of ischemia by placing an aneurysm clip to femoral artery and reperfused after 1, 2 and 4 hours. Seventy-two Wistar-Albino rats were randomly divided into mainly four groups according to treatment agents: Group I (control group) was treated with saline; Group II was treated with diltiazem hydrochloride; Group III was treated with cilostazol in 30% dimethyl sulphoxide; and Group IV was treated with 30% dimethyl sulphoxide intraperitoneally. These four main groups also subdivided into three subgroups according to duration of the reperfusion times. Blood samples were taken and all rats were sacrificed.
Results: Cilostazol-treated groups demonstrated a significant decrease in tissue and serum malondialdehyde (MDA) levels, and tissue myeloperoxidase (MPO ) activity compared with other groups. Increase in serum nitric oxide (NOx) level was significantly higher in all subgroups of cilastazol, diltiazem hydrochloride, and dimethyl sulphoxide groups versus the control group.
Conclusion: Although these results suggest the beneficial effects of cilostazol and diltiazem hydrochloride on I/R injury, the effect of cilostazol on I/R injury seems to be more efficient than diltiazem hydrochloride.
Blaisdell FW. 2002. The pathophysiology of skeletal muscle ischemia and reperfusion syndrome: a review. Cardiovasc Surg 10:620-30.
Buege JA, Aust SD. 1978. Microsomal lipid peroxidation. In: Methods in enzymology. P Fleischer, L Packer (eds). New York: Academic Press. vol. 52, pp. 302-10.
Chan RK, Austen WG Jr, Ibrahim S, et al. 2004. Reperfusion injury to skeletal muscle affects primarily type II muscle fibers. J Surg Research 122:54-60.
Ferrari RS, Andrade CF. 2015. Oxidative stress and lung ischemia-reperfusion injury.
Oxid Med Cell Longev 2015:590987.
Granger DN, Kvietys PR. 2015. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol 6:524-51.
Hakaim AG, Cunningham L, White JL, Hoover K. 1999. Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury. J Trauma 46:869-72.
Hori A, Shibata R, Morisaki K, Murohara T, Komori K. 2012. Cilostazol stimulates revascularisation in response to ischemia via an eNOS-dependent mechanism. Eur J Vasc Endovasc Surg 43:62-5.
Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, Ito Y. 2006. Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 26:522-6.
Kadambi A, Skalak TC. 2000. Role of leukocytes and tissue-derived oxidants in short-term skeletal muscle ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 278:H435-43.
Kalogeris T, Baines CP, Krenz M, Korthuis RJ. 2012. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298:229-317.
Krawisz JE, Sharon P, Stenson WF. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344-50.
Lindsay TF, Liauw S, Romaschin AD, Walker PM. 1990. The effect of ischemia/reperfusion on adenine nucleotide metabolism and xanthine oxidase production in skeletal muscle. J Vasc Surg 12:8-15.
Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. 2011. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 62:15-7.
Östman B, Michaelsson K, Rahme H, Hillered L. 2004. Tourniquet-induced ischemia and reperfusion in human skeletal muscle. Clin Orthop 418:260-5.
Parvuvums DV. 1999. The pathology of ischemia–reperfusion. In: Ischemia–reperfusion injury. PA Grace, RT Mathie (eds). London: Blackwell Science. pp. 3-19.
Rácz IB, Sarkadi L, Hamar J. 1996. The functional damages of ischemia/reperfused skeletal muscle. Acta Physiol Hung 84:205-16.
Rousseau G, St-Jean G, Latour JG, Merhi Y, Nattel S, Waters D. 1991. Diltiazem at reperfusion reduces neutrophil accumulation and infarct size in dogs with ischaemic myocardium. Cardiovasc Res 25:319-29.
Santos MR, Celotto AC, Capellini VK, Evora PR, Piccinato CE, Joviliano EE. 2012. The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. Clinics (Sao Paulo) 67:171-8.
Schlag MG, Harris KA, Potter RF. 2001. Role of leukocyte accumulation and oxygen radicals in ischemia-reperfusion-induced injury in skeletal muscle. Am J Physiol Heart Circ Physiol 280:H1716-21.
Smith PK, Krohn RI, Hermanson GT, et al. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
Takeo S, Tanonaka K, Iwai T, Motegi K, Hirota Y. 2004. Preservation of mitochondrial function during ischemia as a possible mechanism for cardioprotection of diltiazem against ischemia/reperfusion injury. Biochem Pharmacol 67:565-74.
Tran TP, Tu H, Pipinos II, Muelleman RL, Albadawi H, Li YL. 2011. Tourniquet-induced acute ischemia-reperfusion injury in mouse skeletal muscles: involvement of superoxide. Eur J Pharmacol 650:328-34.
Turchányi B, Tóth B, Rácz I, Vendégh Z, Furész J, Hamar J. 2005. Ischemia reperfusion injury of the skeletal muscle after selective deafferentation. Physiol Res 54:25-31.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).